|
|
|
|
Vol. 14, Issue 6, 2372-2384, June 2003



* Institute for Medical Biochemistry, University of Muenster, D-48149 Muenster,
Germany;
Institute for Infectiology, University of Muenster, D-48149 Muenster,
Germany; and
Integrated Functional Genomics, University of Muenster, D-48149 Muenster,
Germany
Submitted September 2, 2002;
Revised December 23, 2002;
Accepted February 5, 2003
Monitoring Editor: Anthony P. Bretcher
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Although not shown in the case of ERM proteins, Ca2+
ions are known to serve important messenger functions in the regulation of
membrane-cytoskeleton contacts and the membrane-underlying cytoskeleton. Among
other things Ca2+ transients regulate the spectrin
binding to NMDA membrane receptors
(Wechsler and Teichberg,
1998
), trigger through activation of calmodulin a disassembly of
cortical F-actin in mast cells (Sullivan
et al., 2000
), and induce cell shape changes in
fertilized Xenopus eggs (Muto and
Mikoshiba, 1998
). Information on proteins transmitting these
Ca2+ signals is scarce, although members of two
multigene families of Ca2+-binding proteins, which are
found in the membrane-underlying cytoskeleton of numerous cells, have been
implicated in Ca2+ stimulus-response coupling in the
cell cortex. Examples are several
Ca2+/phospholipid-binding proteins of the annexin
family, in particular annexins 2 and 6, which are enriched at sites of
cholesterol-rich membrane microdomains
(Oliferenko et al.,
1999
; Babiychuk and Draeger,
2000
; Zobiack et al.,
2002
), and EF hand type Ca2+-binding
proteins like calmodulin (Rogers and
Strehler, 1996
),
-actinin
(Noegel, 1996
), the neuronal
EF hand protein VILIP (Lenz et
al., 1996
), and the penta EF hand protein peflin
(Kitaura et al.,
2001
).
Some evidence also links S100 proteins, which constitute a distinct
subfamily of EF hand type Ca2+-binding proteins to the
regulation of cytoskeleton dynamics and membrane-cytoskeleton interactions.
S100 A1 and B, for example, bind to and possibly regulate actin-associated
proteins like caldesmon and CapZ, S100A10 is required for targeting the
membrane and F-actin binding protein annexin 2 to the cortical cytoskeleton
and S100A8, 9, and 12 translocate to the plasma membrane upon
Ca2+ elevation in leukocytes (for reviews see
Donato, 2001
;
Heizmann et al.,
2002
). However, functional information on the role of S100
proteins in membrane-cytoskeleton dynamics is very limited. Moreover, most
binding partners of S100 proteins have so far only been described in in vitro
studies with intrinsic limitations as to the specificity of the interactions.
Despite this lack of functional information S100 proteins are structurally
well characterized. They consist of two EF hand
Ca2+-binding motifs that are connected via a flexible
linker and flanked by N- and C-terminal extensions. Typically, S100 proteins
form homodimers and structural evidence strongly indicates that it is only the
S100 dimer that interacts with and thereby regulates target proteins in a
Ca2+-dependent manner
(Rety et al., 1999
;
Rety et al., 2000
;
Rustandi et al.,
2000
).
These structural findings led us develop an approach for identifying
specific binding partners of S100 proteins, i.e., those that will only
interact with the biologically active S100 dimer. We constructed affinity
matrices, based on our identification of a mutant S100P protein that fails to
engage in dimer formation (Koltzscher and
Gerke, 2000
), containing either the wild-type dimeric or mutant
monomeric S100 protein and identified in a placental extract ezrin as a
specific binding partner only interacting with dimeric S100P. The interaction
is Ca2+ dependent, observed for dormant ezrin, and
mediated through the N-terminal ezrin domain. Importantly, binding to S100P
unmasks the F-actin binding site in dormant ezrin. Using GFP-tagged S100P
derivatives we also show that upon Ca2+ elevation in
human A431 cells the dimeric but not the monomeric S100 protein translocates
to the cell cortex showing a colocalization with ezrin. Thus, by means of
triggering complex formation between S100P and ezrin elevations in cellular
Ca2+ levels could directly affect ezrin function in the
cell cortex.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Recombinant Expression and Purification of S100P and Ezrin
pET 28a+ constructs encoding WT S100P, F15A S100P, WT ezrin, and ezrin
deletion mutants with N-terminal histidine tags were used to transform
Escherichia coli cells [strain BL21(DE3)pLysS]. Transformed bacteria
were grown to an OD600 of 0.6, and recombinant protein expression
was then induced by adding IPTG to a concentration of 1 mM. After incubation
for an additional 3 h, cells were harvested by centrifugation (5000 x
g; 10 min) and resuspended in lysis buffer (50 mM Tris-Cl, pH 7.5;
300 mM NaCl; 20 mM imidazole-HCl, pH 7.5; 1 mM EDTA; 10 mM
-mercaptoethanol; 1 mM PMSF; 10 µM leupeptin). For preparation of WT
S100P and F15A S100P cells were lysed by repeated freeze/thaw cycles (3 times)
and sonication. The lysate was centrifuged for 1 h at 100,000 x
g, and the remaining supernatant was made 5 mM in
Ca2+ and applied to a phenyl-sepharose (Pharmacia,
Freiburg, Germany) column equilibrated in lysis buffer containing 0.5 mM
Ca2+ and no EDTA. After extensive washing with the same
buffer, bound WT S100P protein was eluted with lysis buffer containing 1 mM
EGTA, whereas F15A S100P protein was eluted with 30% isopropanole in lysis
buffer containing 1 mM EGTA. S100P-containing fractions were pooled, dialyzed
against 20 mM imidazole, pH 7.5, 300 mM NaCl, 10 mM
-mercaptoethanol,
and 1 mM PMSF, and applied to a Ni-NTA-agarose (Qiagen, Hilden, Germany)
column equilibrated in the same buffer. S100P proteins were eluted with 250 mM
imidazole, pH 7.5, 300 mM NaCl, 10 mM
-mercaptoethanol, and 1 mM
PMSF.
For preparation of WT ezrin and ezrin deletion mutants cells were lysed
only by sonication. The lysates were centrifuged for 1 h at 100,000 x
g, and the supernatants were applied to a Ni-NTA agarose column
equilibrated in lysis buffer. After washing with lysis buffer containing 35 mM
imidazole, pH 7.5, bound ezrin proteins were eluted with 300 mM imidazole, pH
7.5, 300 mM NaCl, 10 mM
-mercaptoethanol, and 1 mM PMSF.
Preparation of Placental Protein Extracts
Twenty-five grams of frozen placenta were homogenized using a Waring
blender in 180 ml of homogenization buffer (30 mM HEPES, pH 7.2; 140 mM NaCl;
2 mM MgCl2; 1% Triton X-100; 1 mM DTT; 1 mM EDTA; 10 µg/ml
pepstatin; 35 µg/ml aprotinin; 3 µM leupeptin; 0.5 µg/ml TPCK; 1.5 mM
PMSF). The homogenate was clarified by centrifugation at 22,000 x
g for 30 min at 4°C, and the resulting supernatant was further
centrifuged at 100,000 x g for 1 h at 4°C. The lysate was
dialyzed three times against 50 volumes of buffer D (30 mM HEPES, pH 7.2; 20
mM imidazole, pH 7.2; 300 mM NaCl; 2 mM MgCl2; 10 mM
-mercaptoethanol; 10 µg/ml pepstatin; 35 µg/ml aprotinin; 3 µM
leupeptin; 0.5 µg/ml TPCK; 1.5 mM PMSF; 2 mM NaN3). The extract
obtained typically had a protein concentration of
5 mg/ml.
Affinity Chromatography of Placental Proteins on Immobilized
S100P
To generate an affinity column, His-tagged WT S100P protein was immobilized
on Ni-NTA agarose. In parallel a second affinity column was prepared using the
His-tagged mutant protein F15A S100P. The latter served as a control, because
the mutant albeit folding correctly was incapable of forming dimers neither
with itself nor with the WT S100P protein
(Koltzscher and Gerke,
2000
).
Five milligrams of purified, His-tagged WT S100P or F15A S100P,
respectively, was dialyzed against buffer C (30 mM HEPES, pH 7.2; 20 mM
imidazole, pH 7.2; 300 mM NaCl; 2 mM MgCl2; 0.5 mM
CaCl2; 10 mM
-mercaptoethanol; 10 µg/ml pepstatin; 35
µg/ml aprotinin; 3 µM leupeptin; 0.5 µg/ml TPCK; 1.5 mM PMSF; 2 mM
NaN3), added to 2 ml Ni-NTA-agarose equilibrated in the same buffer
and incubated overnight at 4°C with gentle inversion. The
Ni-NTA-agarose/S100P protein slurries were then transferred to 10-ml
polypropylene columns (Pierce, Rockford, IL) and washed with 10 column volumes
of buffer C to remove unbound protein. Before loading and while gentle
stirring, CaCl2 was added carefully to the placental protein
extract to a final concentration of 0.7 mM. Thirty milligrams of placental
protein extract was then loaded onto each chromatography column. The columns
were washed with 10 column volumes of buffer C, 10 column volumes buffer C1
(same as buffer C except that it contained 0.7 mM EGTA instead of 0.5 mM
CaCl2) to elute proteins bound in a
Ca2+-dependent manner and finally with 10 column volumes
of buffer C2 (same as buffer C1 but with 250 mM imidazole, pH 7.2, instead of
only 20 mM) to remove from the columns the His-tag bound proteins and
Ca2+-independent interaction partners. Fractions were
collected throughout, and aliquots were analyzed in gradient (715%)
SDS-polyacrylamide gels stained with Coomassie brilliant blue
(Laemmli, 1970
).
MALDI-TOF Analysis and Database Searches
After SDS-PAGE the protein band of interest was prepared for mass
spectrometry in a procedure modified from Shevchenko et al.
(1996
) and Zhang et
al. (1998
). A gel slice
containing the protein band was excised and destained in 25 mM
NH4HCO3 containing 50% methanol. It was washed in acetic
acid/methanol/water (10/45/45 vol/vol/vol) for 30 min and in water for 30 min.
Subsequently it was shrunk in acetonitrile and dried. The gel pieces were then
reswollen in 20 µl of 40 mM NH4HCO3 containing 400 ng
trypsin (BoehringerMannheim, Mannheim, Germany). After 30 min of incubation,
extra trypsin solution was removed, and 50 mM NH4HCO3
was added to cover the gel. Digestion was carried out at 37°C overnight.
The supernatant was then transferred to a clean Eppendorf tube and peptides
were extracted three times with 70 µl acetonitrile/water/formic acid
(50/45/5 vol/vol/vol). Supernatants were pooled and lyophilized. The dried
extract was redissolved in 7 µl water/acetonitrile (95/5 vol/vol)
containing 0.1% trifluoric acid (TFA; Merck, Darmstadt, Germany) and purified
using ZipTips (Millipore, Bedford, MA). Peptides were eluted with 8 µl
acetonitrile/0.1% aqueous TFA (70/30 vol/vol). For matrix preparation, 10 mg
-cyano-4-hydroxycinnamic acid (
-cyano; Sigma, Deisenhofen,
Germany) were washed with acetone and dissolved in 1 ml of 49.5/49.5/1
(vol/vol/vol) acetonitrile/ethanol/0.1% aqueous TFA. 0.5 µl of this matrix
preparation was spotted onto the target, followed by the same amount of
peptide sample, and both solutions were mixed directly on the target for MALDI
peptide mapping on TofSpec 2E (Micromass Ltd., Manchester, UK). Digests were
run in positive ion reflectron mode using a matrix suppression of 500. Masses
were externally calibrated and internally corrected using the lock mass option
of the instrument providing m/z values better than 50 ppm up to m/z 2500.
Nanospray-MS/MS of tryptic peptides was performed using iontrap (Bruker
Daltonics, Bremen, Germany) and Q-TOF (Micromass, Manchester, UK), kindly made
available to us by Prof. J. Peter-Katalinic (Institute of Medical Physics and
Biophysics, University of Münster).
Database searches were performed using either ProteinProbe (Micromass) locally or Mascot (Matrix Science, London, UK) and Protein Prospector (University of California, San Francisco, CA), available to the public on the internet. Databases searched were SwissProt (University of Geneva and European Bioinformatics Institut), NCBI (National Center of Bioinformatics, Bethesda, MD), or OWL (University of Leeds, UK). BLAST2.0 searches were carried out at the Swiss Institute of Bioinformatics (SIB).
In Vitro Binding Assays
The interaction between S100P and ezrin was analyzed by using affinity
columns containing one of the binding partners in an immobilized form. To
prepare affinity columns, purified His-tagged proteins (S100P, ezrin, and
their mutant derivatives) were dialyzed against buffer A (30 mM HEPES, pH 7.2;
25 mM imidazole, pH 7.2; 150 mM NaCl; 1 mM MgCl2; 0.5 mM
CaCl2; 10 mM
-mercaptoethanol; 1.5 mM PMSF) and rebound to
Ni-NTA agarose. In each case 300 µg of purified His-tagged protein, WT
S100P, F15A S100P, WT ezrin, N-ERMAD, and C-ERMAD, respectively, were mixed
with 250 µl of a 50% Ni-NTA agarose slurry equilibrated in buffer A and
incubated for at least 2 h at 4°C with gentle agitation. The mixtures were
then transferred to 2-ml polypropylene columns (Pierce) and washed with buffer
A to remove unbound protein. In the case of immobilized WT S100P or F15A
S100P, purified and thrombin-cleaved WT ezrin, N-ERMAD, or C-ERMAD protein
(
100 µg each, in buffer A) were added to the column in the fluid
phase. After washing with buffer A (10 column volumes),
Ca2+-dependently bound proteins were eluted with 10
column volumes of buffer B (same as buffer A but containing 0.7 mM EGTA
instead of 0.5 mM CaCl2), and the columns were then stripped of
His-tagged proteins by elution with 10 volumes of buffer E (same as buffer B
but with 250 mM imidazole instead of only 25 mM). The vice versa experiments,
using immobilized WT ezrin, were performed in a corresponding manner using in
the fluid phase thrombin-cleaved WT S100P or F15A S100P and as further
controls recombinantly expressed untagged WT S100P
(Becker et al., 1992
),
untagged WT S100A1 (Osterloh et
al., 1998
), and untagged WT S100A11
(Seemann et al.,
1996
). Aliquots of each wash and elution fraction were analyzed by
12.5% Tris/tricine SDS-PAGE (Schägger
and von Jagow, 1987
), and the gels were stained with
Coomassie.
Thrombin Cleavage of Purified Proteins
About 0.21 mg of purified His-tagged proteins were mixed in buffer A
(without PMSF) with 0.10.5 ml Ni-NTA agarose, and proteins were allowed
to bind at 4°C for at least 2 h. The mixtures were then centrifuged at
2500 rpm in a microcentrifuge for 5 min at 4°C, the supernatants removed,
and the pellets washed two times with buffer A (without PMSF). The final
pellets were resuspended in buffer A (without PMSF) at a protein concentration
of 3 µg/µl and 0.20.8 U thrombin (Sigma) were added to the
slurry. After incubation at 37°C for 2 h, the Ni-NTA agarose was pelleted
in a microcentrifuge (2500 rpm, 5 min, 4°C), and the thrombin-cleaved
proteins lacking the His-tag were recovered in the supernatants. To inhibit
further thrombin activity the supernatants were made 1.5 mM in PMSF. Recovery
of cleaved protein was
90% as judged by SDS-PAGE.
F-actin Binding Assay
G-actin, 100 µg, in buffer G (5 mM Tris-HCl, pH 8.0; 0.2 mM ATP; 0.5 mM
DTT; 0.2 mM CaCl2) were mixed with 10 µg WT ezrin either alone
or in the presence of 10 µg WT S100P or F15A S100P, respectively, in a
total volume of 50 µl. Experiments were carried out in the presence of
Ca2+ by adding 4 µl of 45 mM CaCl2 (final
concentration
3 mM) or in the absence of Ca2+ by
adding 4 µl 100 mM EGTA (final concentration
6.6 mM). F-actin
polymerization was then induced by adding 6 µl of 10x polymerization
buffer (20 mM Tris-HCl, pH 8.8; 500 mM KCl; 10 mM ATP; 20 mM MgCl2)
and the reaction was incubated for 3 h at 20°C. After high-speed
centrifugation (150,000 x g, 1 h, 4°C), the supernatant was
collected and the F-actin pellet was resuspended in 60 µl 1 x
polymerization buffer (with or without Ca2+/EGTA) and
centrifuged again (150,000 x g, 1 h, 4°C). The supernatant
was removed and the pellet was resuspended in 60 µl of SDS-PAGE sample
buffer. Equivalent aliquots of the supernatant and pellet fractions were
subjected to SDS-PAGE in 12.5% Tris/tricine gels followed by Coomassie
brilliant blue staining. Dried gels were then analyzed on a Lumi-Imager F1
using the LumiAnalyst software (Boehringer Mannheim) for quantification of
visible bands.
Cell Transfection and Immunofluorescence Microscopy
A431 cells were maintained in DME medium supplemented with 10% FCS, 1%
L-glutamine and antibiotics. Transient transfection of pEGFP
plasmids encoding the fusion proteins GFP-WT S100P and GFP-F15A S100P,
respectively, was carried out by electroporation (250 V, 900 µF) of
trypsinized cells in 4-mm cuvettes. After transfection cells were seeded on
coverslips and allowed to express the recombinant protein for 3 d. Cells were
then fixed with 3% formaldehyde in PBS for 20 min at room temperature. After
quenching in 50 mM NH4Cl for 10 min cells were permeabilized with
0.2% Triton X-100 in PBS for 10 min and incubated in PBS supplemented with 5%
BSA for 30 min. Cells were then incubated with affinity-purified antiezrin
antibodies (B23, gift from A. Bretscher) for 30 min and washed three times
with PBS/5% BSA, and primary antibodies were stained with Cy3-conjugated goat
anti-rabbit secondary antibodies (Jackson ImmunoResearch, Dianova, Hamburg,
Germany). Cells were washed three times with PBS, once with distilled
H2O, mounted in Mowiol, and analyzed using a confocal laser
scanning microscope (Zeiss, Jena, Germany; LSM 510).
EGF and A23187 Treatment of A431 Cells
Transiently transfected cells grown on coverslips were transferred to DMEM
without FCS and cultured for 612 h. EGF or A23187
[GenBank]
were then added at a
final concentration of 10 µg/ml and 1 µM, respectively. Cells were
incubated for 215 min (EGF) or 1 min (A23187
[GenBank]
), fixed, and processed for
immunofluorescence microscopy.
| RESULTS |
|---|
|
|
|---|
80 kDa is recovered only in the eluate
of the WT S100P column (Figure
1, compare lanes 4 and 9). This 80-kDa protein therefore
represents the candidate of a specific target only interacting with the
dimeric S100P in a Ca2+-dependent manner.
|
To identify the nature of the 80-kDa band, it was excised from the gel and
subjected to in-gel trypsin digestion and subsequent MALDI-MS for peptide mass
fingerprinting (our unpublished results). Database searches of the mass
profiles obtained revealed that they matched those of human ezrin. This
identification was corroborated by sequence information of a number of
peptides analyzed by nanospray MS/MS. None of the peptide sequences obtained
matched those of other members of the ERM family which are also present in
placental extracts (Bretscher,
1989
; Lankes and Furthmayr,
1991
).
Ca2+-bound S100P Directly Interacts with Ezrin
To elucidate whether S100P and ezrin directly interact with one another or
whether other placental proteins participate in forming a higher-order complex
retained on the affinity column, we performed binding assays with purified
ezrin and S100P. In a first set of experiments immobilized S100P (WT or F15A
mutant) was incubated in the presence of Ca2+ with
purified ezrin generated by recombinant expression of a His-tagged version and
subsequent removal of the His tag through thrombin cleavage.
Figure 2, A and B, reveals that
ezrin is retained in a Ca2+-dependent manner, i.e., can
be eluted with an EGTA-containing buffer, on the WT but not the F15A S100P
column. This shows that ezrin binds directly to S100P with the interaction
being specific for the dimeric S100P protein. We also used lysates from
bacteria expressing a nontagged version of WT ezrin instead of the purified
and thrombin-cleaved protein in the same set of experiments. Identical results
regarding the dimer-specific and Ca2+-dependent binding
to S100P were obtained, revealing that the authentic ezrin is capable of
binding S100P directly (our unpublished results).
|
Next, we performed the binding experiments in the opposite order, i.e., His-tagged ezrin was immobilized on Ni-Agarose beads and incubated in the presence of Ca2+ with purified WT or mutant S100P. Again, a specific and direct interaction can be observed. Although WT S100P binds to the ezrin matrix in the presence of Ca2+ and is released upon treatment with EGTA, F15A S100P fails to be retained and is recovered exclusively in the flow through and wash fractions (Figure 2, C and D). To include additional specificity controls, we tested whether other dimeric S100 proteins are capable of binding ezrin. Therefore purified S100A1 and S100A11 were incubated with the ezrin matrix and any Ca2+-dependently bound protein was released with EGTA. Figure 2, E and F, reveals that in both cases no protein is retained on the matrix, indicating that the interaction of ezrin with S100P is specific for this member of the S100 protein family.
S100P Binds to the N-terminal Domain of Ezrin
Ezrin consists of two principal domains, an N-terminal domain (N-ERMAD)
capable of binding EBP50 (ERM-binding phosphoprotein 50) and a number of
membrane proteins and a C-terminal domain (C-ERMAD) harboring the F-actin
binding site (for reviews see Bretscher et al.,
2000
,
2002
;
Tsukita et al., 1997
;
Mangeat et al.,
1999
). To elucidate whether the S100P binding site maps to one of
these domains, N-ERMAD and C-ERMAD of ezrin were expressed recombinantly,
purified, and applied to columns containing immobilized WT or F15A S100P,
respectively. Incubations were carried out in the presence of
Ca2+ and after extensive washing the columns were eluted
with EGTA- and then imidazole-containing buffers, i.e., experimental
conditions were identical to those applied for full length ezrin.
Figure 3 shows that only
N-ERMAD is retained on the column in a Ca2+-dependent
manner, thereby identifying N-ERMAD as the site of S100P interaction. Again
the interaction is specific for the dimeric S100P molecule.
|
The EzrinF-actin Interaction Is Regulated by S100P
The binding assays described above were carried out with nonphosphorylated
and thus nonactive or dormant ezrin and revealed that S100P in contrast to
most other protein-binding partners of ezrin is capable of interacting with
the dormant molecule. Because S100 proteins are thought to participate in
stimulus-response coupling by regulating activities of their respective
targets upon Ca2+-triggered binding, we next sought to
determine whether the Ca2+-dependent binding of S100P to
ezrin results in an altered activity of the dormant ezrin. A property
typically affected upon phosphorylation-dependent activation of ezrin is its
F-actin binding. Although dormant ezrin does not interact with F-actin,
threonine phosphorylation in the C-terminal domain unmasks the F-actin binding
site (Simons et al.,
1998
; Nakamura et
al., 1999
). Therefore we analyzed whether the ability of
ezrin to interact with F-actin is affected when it resides in a complex with
S100P. F-actin cosedimentation assays were carried out with purified ezrin and
WT or F15A S100P in the presence or absence of Ca2+.
Figure 4 reveals that a
significant fraction of ezrin cosediments with F-actin in the presence of WT
but not F15A S100P. This cosedimentation is not observed in the absence of
S100P, thus revealing that the ezrin used in the assays is in its dormant
conformation and not activated by mild proteolysis
(Figure 4B). As estimated by
densitometric scanning, the stoichiometry of ezrin to actin in the pellet
fraction (lane 3) is approximately 1:10 and thus in the range of what has been
observed previously in F-actin binding experiments
(Yao et al., 1996
;
Roy et al., 1997
).
Increasing in the cosedimentation assay the amount of actin also leads to an
increased amount of copelleted ezrin, with the estimated stoichiometry
remaining at 1:10 (ezrin-actin; our unpublished results). The ezrin-F-actin
cosedimentation is Ca2+ dependent and most likely due to
S100P-ezrin complex formation because a fraction of WT S100P but not the
monomeric mutant molecule is recovered together with ezrin in the F-actin
sediment. Such F-actin cosedimentation of S100P is not seen in the absence of
ezrin or Ca2+ (Figure
4B). Thus, the Ca2+-regulated binding of
S100P to ezrin can expose the F-actin binding site in a manner not depending
on PIP2 binding and threonine phosphorylation.
|
S100P and Ezrin Colocalize in Stimulated A431 Cells
In a number of cells ezrin has been localized to the plasma membrane, in
particular to areas where actin filaments are concentrated, e.g., microvilli,
membrane ruffles, and cell adhesion sites (see, for example,
Bonilha et al., 1999
;
Bretscher, 1999
;
Yonemura et al.,
1999
; Gautreau et
al., 2000
). This localization is dependent on an activation
of the dormant ezrin that resides in the cytosol. In A431 human epidermoid
cells a cytosol-membrane translocation of ezrin is observed in response to
EGF, and EGF also triggers an elongation of microvilli in A431 cells
overexpressing ERM binding membrane proteins
(Bretscher, 1989
;
Yonemura et al.,
1999
). Therefore we chose A431 cells cultivated in the absence or
presence of EGF to study the intracellular localization of S100P in comparison
to that of ezrin. Although we used different antigen preparations and
immunization strategies, we could not obtain high-affinity anti-S100P
antibodies not cross-reacting with other members of the S100 family. Therefore
we recorded the distribution of S100P within A431 cells by ectopically
expressing a GFP-S100P fusion protein. In this chimera the GFP was fused to
the N-terminus of S100P because we had shown previously for another S100
protein (S100A10) that an N-terminal GFP tag did not affect biochemical
properties or intracellular localization of the S100 protein
(Zobiack et al.,
2001
).
Cells expressing GFP-WT S100P show a diffuse general GFP signal when kept in serum-free medium. Likewise, ezrin is found throughout the cytoplasm and is not concentrated at the plasma membrane under these conditions (Figure 5). When cells are exposed to EGF for 2 or 15 min, a considerable fraction of the ezrin translocates to areas beneath the plasma membrane, showing a particular enrichment at sites of membrane ruffles and microvilli. GFP-WT S100P also shows a partial membrane localization in the EGF-treated cells, and this membrane-associated GFP-WT S100P colocalizes with ezrin (Figure 6, top panels). In contrast, a GFP chimera of the F15A S100P mutant protein (GFP-F15A S100P) remains cytosolic after EGF stimulation (Figure 6, bottom panels). The intracellular distribution of the different GFP-S100P derivatives (WT and F15A) was also recorded in cells cultivated in serum. Similar to the EGF stimulus, these conditions induce a partial membrane localization of WT S100P that is not observed for the F15A S100P mutant. Again staining of the membrane associated S100P overlaps with that of ezrin (our unpublished results).
|
|
The experiments described above establish that ezrin and S100P show
partially overlapping distributions in serum- and EGF-stimulated cells and
that this requires an intact ezrin binding site in S100P, i.e., formation of
the biologically active dimer. The EGF treatment of A431 cells carried out
here is known to elicit a rapid and sustained rise in intracellular
Ca2+ but also triggers other signaling events
(Hepler et al., 1987
;
Hughes et al., 1991
).
Thus, the conditions chosen do not allow to analyze directly the contribution
of Ca2+ signaling to the translocation of S100P and
ezrin. To address this point we treated A431 cells with the
Ca2+ ionophore A23187
[GenBank]
, which enabled us to increase
intracellular Ca2+ concentrations without initiating
signaling events through the activation of growth factor receptors.
Figure 7 reveals that treatment
with the Ca2+ ionophore also induces a significant
recruitment of ezrin to the cell periphery. Moreover, a marked increase in the
number of microvilli and membrane ruffles is observed in phase images of the
ionophore-treated cells (our unpublished results) with the membrane extensions
being positive for ezrin. Concomitantly, some WT but not F15A S100P is
translocated to the cell periphery and the microvillar protrusions
(Figure 7). This parallel and
Ca2+-induced translocation indicates that the
Ca2+-regulated binding of S100P to ezrin could directly
activate dormant ezrin molecules within cells.
|
| DISCUSSION |
|---|
|
|
|---|
The specific interaction between dimeric S100P and ezrin not only
underscores the validity of our approach but is also the first identification
of a target protein for S100P. S100P is a member of the family initially
isolated from placental tissue (Becker
et al., 1992
; Emoto
et al., 1992
). Through RT-PCR and EST analyses, it has
recently also been identified in a number of other tissues and cells,
including A431 (Amler et al.,
2000
; Guerreiro Da Silva
et al., 2000
; M. Koltzscher and V. Gerke, unpublished
observation). All S100P-expressing tissues reported so far contain ezrin at
least in their epithelial cell layers
(Berryman et al.,
1993
), thus indicating that the interaction reported here could be
of relevance in a number of cells.
Our analysis identifies S100P as one of the few ligands capable of
interacting with ezrin in its dormant conformation. This interaction is seen
with the two proteins expressed recombinantly in bacteria and also in
placental extracts when endogenous ezrin is affinity selected by immobilized
S100P (see Figure 1). Binding
of S100P occurs via the N-ERMAD of ezrin, which also contains the binding
sites for membrane proteins and EBP-50. However, it appears unlikely that the
binding sites for these ligands overlap with that of S100P to a substantial
degree because the former but not the latter are masked in dormant ezrin.
Another binding partner of dormant ezrin is the regulatory subunit of type II
cAMP-dependent protein kinase. Here the binding region has been mapped to
residues 373439, i.e., to a sequence outside of N-ERMAD, thus
indicating that dormant ezrin can engage in different types of protein
interactions (Dransfield et al.,
1997
). Unmasking of the binding sites in dormant ezrin and the
resulting activation of the membrane-cytoskeleton linking function of ezrin
requires conformational changes that can be triggered by binding of
phosphatidylinositol 4,5-bisphosphate to the N-terminal domain and/or
phosphorylation of a conserved threonine in the C-ERMAD
(Niggli et al., 1995
;
Nakamura et al.,
1999
; Hamada et al.,
2000
). Because the interaction with S100P also activates ezrin's
F-actin binding, similar conformational changes are likely to occur as a
consequence of but not before ezrin-S100P complex formation.
In several cells including A431 signaling via activated growth factor
receptors has been shown to lead to ezrin phosphorylation, in this case on
tyrosine residues, and to a redistribution of ezrin to microvilli, which are
induced by this treatment (Bretscher,
1989
; Krieg and Hunter,
1992
). However, replacement of the tyrosine phosphorylation sites
by phenylalanine does not alter the microvillar localization of ezrin in
EGF-stimulated cells indicating that tyrosine phosphorylation does not
directly activate dormant ezrin and thus its membrane/cytoskeleton association
(Crepaldi et al.,
1997
). Because EGF stimulation also triggers an increase in
intracellular Ca2+, the
Ca2+-dependent activation of ezrin by S100P could
participate in mediating morphological changes induced by ezrin translocation
in EGF-treated cells. Such Ca2+-triggered activation of
ezrin's cross-linking function is supported by experiments using the
Ca2+ ionophore A23187
[GenBank]
to elevate intracellular
Ca2+-independent of an activation of growth factor
receptors. Ionophore treatment and the resulting Ca2+
rise induce not only a recruitment of ezrin to the cell periphery but also an
increase in the number of microvillar protrusions
(Figure 7). To some extent this
resembles the scenario observed in retinal pigment epithelial cells
overexpressing transfected ezrin (Bonilha
et al., 1999
) and in LLCPK cells ectopically expressing a
(presumably permanently activated) T567D ezrin mutant
(Gautreau et al.,
2000
). Thus the induction of microvilli and membrane ruffles
observed in Ca2+ ionophoretreated cells is likely
to be a consequence of ezrin activation, which in turn could be mediated by
Ca2+-bound S100P.
Complex formation between Ca2+-bound S100P and ezrin
could be stable or transient in nature. A more transient interaction would be
in line with the observation that colocalization of ezrin and S100P in the
cell periphery is limited in stimulated A431 cells (Figures
6 and
7). What parameters could
participate in rendering the S100P-ezrin interaction transient? Our
biochemical data only reveal stable complexes capable of binding F-actin. Thus
the activation of ezrin's cytoskeleton binding does not alter the affinity for
S100P. However, S100P-dependent activation of the F-actin binding site in
C-ERMAD could result from a conformational change resembling the separation of
N- and C-ERMAD induced by Thr-567 phosphorylation or PIP2 binding
(Hamada et al., 2000
;
Pearson et al.,
2000
). As a consequence the N-ERMAD and the central
-helical domain of S100P-bound ezrin will be accessible to binding
partners like type-1 transmembrane proteins, EBP-50, and the recently
identified palladin (Mykkänen et
al., 2001
), and such binding could in turn render the binding
of S100P less stable. However, at present we cannot exclude the possibility
that S100P binding to ezrin only unmasks the F-actin binding site without
disrupting the N-/C-ERMAD interaction. Future experiments analyzing ezrin's
conformational changes induced by S100P binding and reconstituting
multiprotein complexes of ezrin with various ligands under defined conditions
have to address this question.
| ACKNOWLEDGMENTS |
|---|
|
|
|---|
Corresponding author. E-mail address:
gerke{at}uni-muenster.de.
| REFERENCES |
|---|
|
|
|---|
Babiychuk, E.B., and Draeger, A. (2000). Annexins in
cell membrane dynamics: Ca(2+)-regulated association of lipid microdomains.
J. Cell Biol. 150,
1113-1124.
Becker, T., Gerke, V., Kube, E., and Weber, K. (1992). S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur. J. Biochem. 207, 541-547.[Medline]
Berryman, M., Franck, Z., and Bretscher, A. (1993). Ezrin is concentrated in the apical microvilli of a wide variety of epithelial cells whereas moesin is found primarily in endothelial cells. J. Cell Sci. 105, 1025-1043.[Abstract]
Bonilha, V.L., Finnemann, S.C., and Rodriguez-Boulan, E.
(1999). Ezrin promotes morphogenesis of apical microvilli and
basal infoldings in retinal pigment epithelium. J. Cell Biol.
147,
1533-1547.
Bretscher, A. (1989). Rapid phosphorylation and
reorganization of ezrin and spectrin accompany morphological changes induced
in A431 cells by epidermal growth factor. J. Cell Biol.
108,
921-930.
Bretscher, A. (1999). Regulation of cortical structure by the ezrinradixin-moesin protein family. Curr. Opin. Cell Biol. 11, 109-116.[CrossRef][Medline]
Bretscher, A., Edwards, K., and Fehon, R.G. (2002). ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell. Biol. 3, 586-599.[CrossRef][Medline]
Bretscher, A., Chambers, D., Nguyen, R., and Reczek, D. (2000). ERM-merlin and EBP50 protein families in plasma membrane organization and function. Annu. Rev. Cell Dev. Biol. 16, 113-143.[CrossRef][Medline]
Crepaldi, T., Gautreau, A., Comoglio, P.M., Louvard, C., and Arpin,
M. (1997). Ezrin is an effector of hepatocyte growth
factor-mediated migration and morphogenesis in epithelial cells. J.
Cell Biol. 138,
423-434.
Donato, R. (2001). S100: a multigene family of calcium-modulated proteins of the EF hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33, 637-668.[CrossRef][Medline]
Dransfield, D.T., Bradford, A.J., Smith, J., Martin, M., Roy, C., Mangeat, P.H., and Goldenring, J.R. (1997). Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J. 16, 35-43.[CrossRef][Medline]
Emoto, Y., Kobayashi, R., Akatsika, H., and Hidaka, H. (1992). Purification and characterization of a new member of the S-100 protein family from human placenta. Biochem. Biophys. Res. Commun. 182, 1246-1253.[CrossRef][Medline]
Gautreau, A., Louvard, D., and Arpin, M. (2002). ERM proteins and the NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr. Opin. Cell Biol. 14, 104-109.[CrossRef][Medline]
Gautreau, A., Louvard, D., and Arpin, M. (2000).
Morphogenic effects of ezrin require a phosphorylation-induced transition from
oligomers to monomers at the plasma membrane. J. Cell Biol.
150,
193-203.
Gribenko, A.V., Guzman-Casado, M., Lopez, M.M., and Makhatadze,
G.I. (2002). Conformational and thermodynamic properties of
peptide binding to the human S100P protein. Protein Sci.
11,
1367-1375.
Gribenko, A.V., and Makhatadze, G.I. (1998). Oligomerization and divalent ion binding properties of the S100P protein: a Ca2+/Mg2+-switch model. J. Mol. Biol. 283, 679-694.[CrossRef][Medline]
Guerreiro Da Silva, I.D., Hu, Y.F., Russo, I.H., Ao, X., Salicioni, A.M., Yang, X., and Russo, J. (2000). S100P calcium binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int. J. Oncol. 16, 231-240.[Medline]
Hamada, K., Shimizu, T., Matsui, T., Tsukita, S., and Hakoshima, T. (2000). Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain. EMBO J. 19, 4449-4462.[CrossRef][Medline]
Heizmann, C.W., Fritz, G., and Schäfer, B.W. (2002). S100 proteins: structure, functions and pathology. Frontiers Biosci. 7, 1356-1368.[CrossRef]
Hepler, J.R., Nakahata, N., Lovenberg, T.W., DiGuiseppi, J.,
Herman, B., Earp, H.S., and Harden, T.K. (1987). Epidermal growth
factor stimulates the rapid accumulation of inositol (1,4,5)-trisphosphate and
a rise in cytosolic calcium mobilized from intracellular stores in A431 cells.
J. Biol. Chem. 262,
2951-2956.
Hughes, A.R., Bird, G.S., Obie, J.F., Thastrup, O., and Putney, J.W. (1991). Role of inositol (1,4,5)trisphosphate in epidermal growth factor-induced Ca2+ signaling in A431 cells. Mol. Pharmacol. 40, 254-262.[Abstract]
Kitaura, Y., Matsumoto, S., Satoh, H., Hitomi, K., and Maki, M.
(2001). Peflin and ALG-2, members of the penta-EF-hand protein
family, form a heterodimer that dissociates in a Ca2+-dependent manner.
J. Biol. Chem. 276,
14053-14058.
Kligman, D., and Hilt, D.C. (1988). The S-100 protein family. Trends Biochem. Sci. 13, 437-443.[CrossRef][Medline]
Koltzscher, M., and Gerke, V. (2000). Identification of hydrophobic amino acid residues involved in the formation of S100P homodimers in vivo. Biochemistry 39, 9533-9539.[CrossRef][Medline]
Krebs, J., Quadroni, M., and van Eldik, L.J. (1995). Dance of the dimers. Nat. Struct. Biol. 2, 711-714.[CrossRef][Medline]
Krieg, J., and Hunter, T. (1992). Identification of
two major epidermal growth factor-induced tyrosine phosphorylation sites in
the microvillar core protein ezrin. J. Biol. Chem.
267,
19258-19265.
Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.[CrossRef][Medline]
Lankes, W.T., and Furthmayr, H. (1991). Moesin: a
member of the protein 4.1-talin-ezrin family of proteins. Proc. Natl.
Acad. Sci. USA 88,
8297-8301.
Lenz, S.E., Braunawell, K.H., Weise, C., Nedlina-Chittka, A., and Gundelfinger, E. (1996). The neuronal EF-hand Ca(2+)-binding protein VILIP: interaction with cell membrane and actin-based cytoskeleton. Biochem. Biophys. Res. Commun. 225, 1078-1083.[CrossRef][Medline]
Mangeat, P., Roy, C., and Martin, M. (1999). ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol. 9, 187-192.[CrossRef][Medline]
Muto, A., and Mikoshiba, K. (1998). Activation of inositol 1, 4, 5-triphosphate receptors induces transient changes in cell shape of fertilized Xenopus eggs. Cell Motil. Cytoskel. 39, 201-208.[CrossRef][Medline]
Mykkänen, O.-M., Grönholm, M., Rönty, M., Lalowski,
M., Salmikangas, P., Suila, H., and Carpen, O. (2001).
Characterization of human palladin, a microfilament-associated protein.
Mol. Biol. Cell 12,
3060-3073.
Nakamura, F., Huang, L., Pestonjamasp, K., Luna, E.J., and
Furthmayr, H. (1999). Regulation of F-actin binding to platelet
moesin in vitro by both phosphorylation of threonine 558 and
polyphosphatidylinositides. Mol. Biol. Cell
10,
2669-2685.
Niggli, V., Andreoli, C., Roy, C., and Mangeat, P. (1995). Identification of a phosphatidylinositol-4, 5-biphosphate-binding domain in the N-terminal region of ezrin. FEBS Lett. 376, 172-176.[CrossRef][Medline]
Noegel, A.A. (1996). Alpha-actinin. In: Guidebook to the Calcium Binding Proteins, ed. M.R. Celio, Oxford: Oxford University Press, 21-23.
Oliferenko, S., Paiha, K., Harder, T., Gerke, V., Schwarzler, C.,
Schwarz, H., Beug, H., Günthert, U., and Huber, L. (1999).
Analysis of CD44-containing lipid rafts: recruitment of annexin II and
stabilization by the actin cytoskeleton. J. Cell Biol.
146,
843-854.
Osterloh, D., Ivanenkov, V., and Gerke, V. (1998). Hydrophobic residues in the C-terminal extension of S100A1 are essential for target protein binding but not for dimerization. Cell Calcium 24, 137-151.[CrossRef][Medline]
Pearson, M., Reczek, D., Bretscher, A., and Karplus, P. (2000). Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 101, 259-270.[CrossRef][Medline]
Rety, S., Osterloh, D., Arie, J.-P., Tabaries, S., Seemann, J., Russo-Marie, F., Gerke, V., and Lewit-Bentley, A. (2000). Structural basis of the Ca(2+)-dependent association between S100C (S100A11) and its target, the N-terminal part of annexin I. Structure 8, 175-184.[Medline]
Rety, S., Sopkova, J., Renouard, M., Osterloh, D., Tabaries, S., Russo-Marie, F., and Lewit-Bentley, A. (1999). The crystal structure of a complex of p11 with the annexin II N-terminal peptide. Nat. Struct. Biol. 6, 89-95.[CrossRef][Medline]
Rogers, M.S., and Strehler, E.E. (1996). Calmodulin. ed. M.R. Celio, Oxford: Oxford University Press.
Roy, C., Martin, M., and Mangeat, P. (1997). A dual
involvement of the amino-terminal domain of ezrin in F- and G-actin binding.
J. Biol. Chem. 272,
20088-20095.
Rustandi, R.R., Baldisseri, D.M., and Weber, D.J. (2000). Structure of the negative regulatory domain of p53 bound to S100B. Nat. Struct. Biol. 7, 570-574.[CrossRef][Medline]
Schägger, H., and von Jagow, G. (1987). Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166, 368-379.[CrossRef][Medline]
Seemann, J., Weber, K., and Gerke, V. (1996). Structural requirements for annexin I-S100C complex formation. Biochem. J. 319, 123-129.
Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996). Anal. Chem. 68: 850-858.[Medline]
Simons, P.C., Pietromonaco, S.F., Reczek, D., Bretscher, A., and Elias, L. (1998). C-terminal threonine phosphorylation activates ERM proteins to link the cell's cortical lipid bilayer to the cytoskeleton. Biochem. Biophys. Res. Commun. 253, 561-565.[CrossRef][Medline]
Sullivan, R., Burnham, M., Torok, K., and Koffer, A. (2000). Calmodulin regulates the disassembly of cortical F-actin in mast cells but is not required for secretion. Cell Calcium 28, 33-46.[CrossRef][Medline]
Tsukita, S., Yonemura, S., and Tsukita, S. (1997). ERM proteins: head-to-tail regulation of actin-plasma membrane interactions. Trends Biochem. Sci. 22, 53-58.[CrossRef][Medline]
Wechsler, A., and Teichberg, V.I. (1998). Brain spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin. EMBO J. 17, 3931-3939.[CrossRef][Medline]
Yao, X., Cheng, L., and Forte, J.G. (1996).
Biochemical characterization of ezrin-actin interaction. J. Biol.
Chem. 271,
7224-7229.
Yonemura, S., Tsukita, S., and Tsukita, S. (1999). Direct involvement of ezrin/radixin/moesin (ERM)-binding membrane proteins in the organization of microvilli in collaboration with activated ERM proteins. J. Cell Biol. 145, 1497-1509.